Tinurilimab

Tinurilimab (Bay 1834942) binds to human and cynomolgus monkey CEACAM6 with monovalent dissociation constants of K_D of 13 nM and 31 nM, respectively. Tinurilimab is highly selective for human CEACAM6, as it is unable to bind to human CEACAM1, CEACAM3, or CEACAM5^[1].
The half-maximal binding EC₅₀ values for Tinurilimab are determined by flow cytometry in a panel of CEACAM6-expressing cancer cell lines. For Tinurilimab, the EC₅₀ values are in the range of 0.15 nM (PA-TU-8902) to 5 nM (HCC2935)^[1].
Tinurilimab (0-15 μg/mL) blocks the binding of recombinant CEACAM6-Fc to CEACAM1-coated plates in a dose-dependent manner^[1].
Tinurilimab (30 µg/mL) increases type 1 cytokine secretion and the cytotoxic capacity of tumor-specific T cells^[1].
Blockade of CEACAM6 by Tinurilimab (0.01-1000 µg/mL) restored T cell activity in a dose-dependent manner, as evidenced by increased IFN-γ secretion by survivin T cells co-incubated with recombinant CEACAM6-loaded beads^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.